- Economic analysis: Prescription-only status for PSE would drive up physician visits, healthcare costs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- Nexafed gains national distribution
- EXPERT BLOG: Provider status for pharmacists — one way or another
PALATINE, Ill. — Acura Pharmaceuticals on Tuesday announced a study, published in the September issue of the American Journal of Drug and Alcohol Abuse, that validates the ability of Nexafed to uniquely disrupt the extraction and conversion of pseudoephedrine into methamphetamine. The study also confirms that Nexafed delivers the same efficacy compared to other similar PSE products, Acura claimed.
"Nexafed, with its unique Impede technology, was specifically developed to address two key issues: to treat nasal congestion and to fight illicit meth production," stated Albert Brzeczko, lead study author and VP technical affairs with Acura Pharmaceuticals. "With the outcome of this research, we are pleased to confirm that it is effective on both fronts."
When simulating large scale manufacturing to extract and convert pure PSE into meth, researchers found that Nexafed's Impede technology yielded no measurable PSE extraction.
When tested under the popular "one-pot" conversion method, however, the study indicated that current Impede technology tablets had an approximate 38% yield. Currently, Acura Pharmaceuticals is improving its present formulation and developing new Impede 2.0 technology, which yields no measurable amount of meth with the one-pot conversion method in initial testing of a prototype formulation by an outside laboratory.